Abstract
The phagocyte respiratory burst is mediated by the phagocyte NADPH oxidase, a multiprotein subunit complex that facilitates production of reactive oxygen species and which is essential for host defence. Monogenic deficiency of individual subunits leads to chronic granulomatous disease (CGD), which is characterized by an inability to make reactive oxygen species, leading to severe opportunistic infections and auto-inflammation. However, not all cases of CGD are due to mutations in previously identified subunits. We recently showed that Eros, a novel and highly conserved ER-resident transmembrane protein, is essential for the phagocyte respiratory burst in mice because it is required for expression of gp91phox-p22phox heterodimer, which are the membrane bound components of the phagocyte NADPH oxidase. We now show that the function of EROS is conserved in human cells and describe a case of CGD secondary to a homozygous EROS mutation that abolishes EROS protein expression. This work demonstrates the fundamental importance of EROS in human immunity and describes a novel cause of CGD.
Results
The multi-subunit phagocyte NADPH oxidase generates reactive oxygen species and is crucial for host defence 1 and 1bp deletions respectively ( Fig. S1B and C) . Neither clone expressed EROS protein (Fig. 1A) or detectable gp91phox (Fig. 1B) . p22phox expression was also much lower in both EROS-deficient clones than in control cells (Fig. 1C) . We verified the lack of surface gp91phox expression by flow cytometry (Fig. 1D) . Both EROS-deficient clones had a severely impaired respiratory burst (Fig. 1E) . In addition, EROS-deficient clones differentiated towards a neutrophil phenotype also demonstrated an impaired respiratory burst (data not shown). As expected, re-introduction of EROS using a lentiviral vector restored gp91phox expression to EROS-deficient clones ( Figure 1F ) and oxidase activity as measured by Nitro blue tetrazolium chloride (NBT) test ( Figure 1G ) and DIOGENES assay (data not shown).
We then identified a patient with a homozygous C17ORF62/EROS mutation in a resource paper that details a thousand Saudi Arabian families with genetic disease 4 . He presented with fever, splenomegaly, lymphadenopathy and short stature, but no immuno-phenotyping was detailed at that time 4 . His full clinical history is as follows. He is a Saudi Arabian boy, born in 2007, the son of parents in a consanguineous marriage. He has three healthy older sisters.
At 2 months of age, he developed a localized abscess following BCG vaccination. He was then relatively well until 8 years of age but was noted to be of short stature and experienced recurrent pulmonary infections and tonsillitis/pharyngitis despite tonsillectomy.
In August 2015, he became unwell with a febrile illness and an abnormal dihydrorhodamine (DHR) test was noted ( Fig. 2A,B) . He has a severely impaired DHR in response to both PMA and zymosan. He was also profoundly lymphopenic. He subsequently developed an acute Whole exome sequencing demonstrated that the patient had a homozygous (c.127 A to G, NM_001033046) mutation in C17ORF62 (human EROS). His sisters were all heterozygous for this mutation, confirmed by Sanger sequencing (Fig. 2C) . Based on analysis of other family members and the likely important role of C17ORF62 (EROS) in immunity, this mutation was identified as the most likely cause of the patient's disease. The mutation was not present in 10,000 whole genomes from the United Kingdom National Institute for Health
Research BioResource -Rare Disease cohort (which includes 1000 patients with primary immunodeficiency), nor in gnomAD. We therefore performed western blot analysis on anti-CD3-CD28-CD2 expanded T cells from the patient, his sister and a healthy control, as well as primary T cells (either pre or post polyclonal stimulation) and peripheral blood mononuclear cells from healthy volunteers. The CRISPR targeted clones described above were used as positive and negative controls respectively. The patient had undetectable levels of EROS protein compared with cells from the healthy control or the primary T cells/PBMC, while his heterozygous sister had intermediate levels (Fig. 2D) .
Discussion
This work demonstrates that the function of the novel transmembrane protein, Eros, is conserved in humans. It also represents the first description of an immunodeficiency syndrome secondary to mutations in C17ORF62 (human EROS). The severity of the disease seen in this patient underlines the importance of human EROS is for normal immunity. The patient has a clinical history that is compatible with a diagnosis of autosomal recessive CGD, in that he had both infectious and auto-inflammatory manifestations, together with histopathological evidence of granuloma formation in the context of an impaired DHR response.
While recurrent infections, BCG-itis 2,5 , granulomatous inflammation and HLH 6 are all recognised sequelae of CGD, this patient some unusual features such as autoimmune haemolytic anaemia. This is uncommon in CGD and may represent an effect of EROSdeficiency that is independent of its effects on the NAPDH oxidase.
The high sequence similarity between mouse and human EROS and the loss of gp91phox expression and the phagocyte respiratory burst that accompanies its absence suggests that EROS plays an almost identical role in human and murine immunity. In summary, we have
shown that the function of EROS is fully conserved between human and mouse, and that homozygous mutations in EROS underlie a novel sixth cause of chronic granulomatous disease. KGCS oversaw experiments in the project and wrote the manuscript.
